Hainan Honz Pharmaceutical Co (300086) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hainan Honz Pharmaceutical Co (300086) has a cash flow conversion efficiency ratio of -0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-9.17 Million ≈ $-1.34 Million USD) by net assets (CN¥1.07 Billion ≈ $157.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 300086 stock market capitalisation for the company's overall valuation and market capitalisation.
Hainan Honz Pharmaceutical Co - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Hainan Honz Pharmaceutical Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hainan Honz Pharmaceutical Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hainan Honz Pharmaceutical Co ranked by their cash flow conversion efficiency. Explore cash flow quality index of Hainan Honz Pharmaceutical Co to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BRBI BR Partners S.A. ADSs
NASDAQ:BRBI
|
0.136x |
|
Shenzhen Hifuture Electric
SHE:002168
|
-0.484x |
|
China BlueChemical Ltd
F:H1Q
|
0.009x |
|
Zhejiang Tongli Transmission Technology Co. Ltd. A
SHE:301255
|
N/A |
|
Beijing LabTech Instruments Co Ltd
SHG:688056
|
0.014x |
|
Zhejiang Heda Technology Co Ltd
SHG:688296
|
-0.012x |
|
Benz Mining Corp
F:1VU
|
-0.404x |
|
Nepes Corporation
KQ:033640
|
0.041x |
Annual Cash Flow Conversion Efficiency for Hainan Honz Pharmaceutical Co (2007–2025)
The table below shows the annual cash flow conversion efficiency of Hainan Honz Pharmaceutical Co from 2007 to 2025. View 300086 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥921.22 Million ≈ $134.80 Million |
CN¥121.24 Million ≈ $17.74 Million |
0.132x | +114.62% |
| 2024-12-31 | CN¥1.17 Billion ≈ $170.52 Million |
CN¥71.46 Million ≈ $10.46 Million |
0.061x | +19.53% |
| 2023-12-31 | CN¥1.38 Billion ≈ $201.65 Million |
CN¥70.69 Million ≈ $10.34 Million |
0.051x | +137.15% |
| 2022-12-31 | CN¥1.36 Billion ≈ $198.35 Million |
CN¥29.32 Million ≈ $4.29 Million |
0.022x | +196.65% |
| 2021-12-31 | CN¥1.55 Billion ≈ $227.35 Million |
CN¥11.33 Million ≈ $1.66 Million |
0.007x | +169.76% |
| 2020-12-31 | CN¥1.60 Billion ≈ $234.39 Million |
CN¥-16.74 Million ≈ $-2.45 Million |
-0.010x | -137.16% |
| 2019-12-31 | CN¥1.60 Billion ≈ $234.40 Million |
CN¥45.06 Million ≈ $6.59 Million |
0.028x | -70.50% |
| 2018-12-31 | CN¥1.65 Billion ≈ $241.97 Million |
CN¥157.66 Million ≈ $23.07 Million |
0.095x | +907.72% |
| 2017-12-31 | CN¥1.92 Billion ≈ $281.05 Million |
CN¥18.17 Million ≈ $2.66 Million |
0.009x | -80.51% |
| 2016-12-31 | CN¥1.87 Billion ≈ $274.03 Million |
CN¥90.88 Million ≈ $13.30 Million |
0.049x | +14.15% |
| 2015-12-31 | CN¥1.84 Billion ≈ $269.49 Million |
CN¥78.30 Million ≈ $11.46 Million |
0.043x | +3.78% |
| 2014-12-31 | CN¥1.80 Billion ≈ $264.07 Million |
CN¥73.93 Million ≈ $10.82 Million |
0.041x | -6.05% |
| 2013-12-31 | CN¥1.81 Billion ≈ $264.88 Million |
CN¥78.93 Million ≈ $11.55 Million |
0.044x | -25.37% |
| 2012-12-31 | CN¥1.87 Billion ≈ $274.16 Million |
CN¥109.46 Million ≈ $16.02 Million |
0.058x | +207.30% |
| 2011-12-31 | CN¥1.85 Billion ≈ $271.29 Million |
CN¥-100.94 Million ≈ $-14.77 Million |
-0.054x | -224.62% |
| 2010-12-31 | CN¥1.83 Billion ≈ $267.58 Million |
CN¥79.89 Million ≈ $11.69 Million |
0.044x | -88.77% |
| 2009-12-31 | CN¥240.49 Million ≈ $35.19 Million |
CN¥93.58 Million ≈ $13.69 Million |
0.389x | -6.52% |
| 2008-12-31 | CN¥150.41 Million ≈ $22.01 Million |
CN¥62.61 Million ≈ $9.16 Million |
0.416x | +57.69% |
| 2007-12-31 | CN¥115.89 Million ≈ $16.96 Million |
CN¥30.59 Million ≈ $4.48 Million |
0.264x | -- |
About Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pediatric medicines in China and internationally. It operates through Pharmaceutical Manufacturing and Sales; and Daily Necessities Manufacturing and Sales segments. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal, cough … Read more